<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441529</url>
  </required_header>
  <id_info>
    <org_study_id>CR108431</org_study_id>
    <secondary_id>2017-004504-22</secondary_id>
    <secondary_id>64041575RSV1009</secondary_id>
    <nct_id>NCT03441529</nct_id>
  </id_info>
  <brief_title>A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, 2-period, Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the effect of intravenous (IV) infusions of
      piperacillin/tazobactam on the pharmacokinetics (PK) of JNJ-63549109 after a single oral dose
      of lumicitabine in healthy adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Anticipated">April 24, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 24, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of JNJ-63549109 (Metabolite of JNJ-64041575)</measure>
    <time_frame>Predose, 15 minutes (min), 30 min, 1 hour (h), 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>Cmax is the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Plasma Concentration Time Curve From Time Zero to the Last Quantifiable (AUC [0-last]) of JNJ-63549109 (Metabolite of JNJ-64041575)</measure>
    <time_frame>Predose, 15 min, 30 min, 1h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time 0 to the time of the last measurable (non below quantification limit [non BQL]) concentration, calculated by linear trapezoidal summation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-63549109 (Metabolite of JNJ-64041575)</measure>
    <time_frame>Predose, 15 min, 30 min, 1h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time calculated as the sum of AUC (0-last) and C (0-last)/ lambda(z); wherein AUC (0-last) is area under the plasma concentration time curve from time zero to last quantifiable time, C(0-last) is the last observed quantifiable concentration, and lambda (z) is elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-63549109 (Metabolite of JNJ- 64041575)</measure>
    <time_frame>Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>Tmax is the actual sampling time to reach maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Plasma Concentration at 12 Hours Post dose (C12h) of JNJ-63549109 (Metabolite of JNJ- 64041575)</measure>
    <time_frame>12 hours postdose</time_frame>
    <description>C12h is observed plasma concentration at 12 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Plasma Concentration at 24 Hours Post dose (C24h) of JNJ-63549109 (Metabolite of JNJ- 64041575)</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>C24h is observed plasma concentration at 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Rate Constant (Lambda[z]) of JNJ-63549109 (Metabolite of JNJ- 64041575)</measure>
    <time_frame>Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>Lambda[z] is the apparent terminal elimination rate constant, estimated by linear regression using the terminal logarithmic (log)-linear phase of the log-transformed concentration vs time data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half-Life (T1/2) of JNJ-63549109 (Metabolite of JNJ- 64041575)</measure>
    <time_frame>Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>T1/2 is the apparent terminal elimination half-life, calculated as 0.693/Lambda(z).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of JNJ-64167896 (Metabolite of JNJ-64041575)</measure>
    <time_frame>Predose, 15 min, 30 min, 1h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>Cmax is the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration Time Curve From Time Zero to the Last Quantifiable (AUC [0-last]) of JNJ-64167896 (Metabolite of JNJ-64041575)</measure>
    <time_frame>Predose, 15 min, 30 min, 1h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time 0 to the time of the last measurable (non below quantification limit [non BQL]) concentration, calculated by linear trapezoidal summation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-64167896 (Metabolite of JNJ-64041575)</measure>
    <time_frame>Predose, 15 min, 30 min, 1h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time calculated as the sum of AUC (0-last) and C (0-last)/ lambda(z); wherein AUC (0-last) is area under the plasma concentration time curve from time zero to last quantifiable time, C(0-last) is the last observed quantifiable concentration, and lambda (z) is elimination rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to end of study (approximately 2 months)</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ 64167896 (Metabolite of JNJ-64041575)</measure>
    <time_frame>Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>Tmax is the actual sampling time to reach maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Plasma Concentration at 12 Hours Post dose (C12h) of JNJ 64167896 (Metabolite of JNJ-64041575)</measure>
    <time_frame>12 hours postdose</time_frame>
    <description>C12h is observed plasma concentration at 12 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Plasma Concentration at 24 Hours Post dose (C24h) of JNJ 64167896 (Metabolite of JNJ-64041575)</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>C24h is observed plasma concentration at 24 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant (Lambda[z]) of JNJ 64167896 (Metabolite of JNJ-64041575)</measure>
    <time_frame>Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>Lambda[z] is the apparent terminal elimination rate constant, estimated by linear regression using the terminal logarithmic (log)-linear phase of the log-transformed concentration vs time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (T1/2) of JNJ 64167896 (Metabolite of JNJ-64041575)</measure>
    <time_frame>Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 hours and end of study (16 days after last study drug intake or early withdrawal) (approximately 2 months)</time_frame>
    <description>T1/2 is the apparent terminal elimination half-life, calculated as 0.693/Lambda(z).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1 (AB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) on Day 1 of period 1 followed by Treatment B as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) together with piperacillin/tazobactam administered as three 30-minute Intravenous (IV) infusions of 4.5 gram (g) piperacillin/tazobactam (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2 (BA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumicitabine</intervention_name>
    <description>Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.</description>
    <arm_group_label>Treatment Sequence 1 (AB)</arm_group_label>
    <arm_group_label>Treatment Sequence 2 (BA)</arm_group_label>
    <other_name>JNJ-64041575, ALS-008176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/Tazobactam</intervention_name>
    <description>Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.</description>
    <arm_group_label>Treatment Sequence 1 (AB)</arm_group_label>
    <arm_group_label>Treatment Sequence 2 (BA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have a body mass index (BMI); weight in kg divided by the square of
             height in meters) between 18.0 and 30.0 kilogram per square meter (kg/m^2), extremes
             included, and a body weight not less than 50.0 kg, inclusive, at screening

          -  Participant must have a blood pressure between 90 and 140 millimeter of mercury (mmHg)
             systolic, extremes included, and no higher than 90 mmHg diastolic. If blood pressure
             is out of range, 1 repeated assessment is permitted after an additional 5 minutes of
             rest

          -  Participants must have normal values for alanine transaminase (ALT) and aspartate
             aminotransferase (AST) (less than or equal to [&lt;=] 1.0*upper limit of laboratory
             normal range [ULN])

          -  Participant must have a normal renal function (estimated glomerular filtration rate
             [eGFR] greater than or equal to [&gt;=] 90 milliliter per minute per 1.73 square meter
             [mL/min/1.73m^2]) determined by the Chronic Kidney Disease Epidemiology Collaboration
             [CKD-EPI] formula)

          -  A female Participant, except if postmenopausal, must have a negative serum beta human
             chorionic gonadotropin (beta hCG) pregnancy test at screening, and a negative urine
             beta hCG pregnancy test on Day 1 of each treatment period

          -  Participant must be healthy on the basis of medical history, physical examination, 12
             lead electrocardiogram (ECG), vital signs, and laboratory tests performed at screening

        Exclusion Criteria:

          -  Participant has a history of current clinically significant medical illness including
             (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease
             (example, glucose 6 phosphate dehydrogenase deficiency), coagulation disorders
             (including any abnormal bleeding or blood dyscrasias), lipid abnormalities,
             significant pulmonary disease, including bronchospastic respiratory disease, diabetes
             mellitus, hepatic or renal insufficiency, thyroid disease, neurologic or psychiatric
             disease, infection, seizure disorders, or any other illness, that in the
             investigator's and/or sponsor's medical monitor opinion should exclude the participant
             or that could interfere with the interpretation of the study results

          -  Participant has a history of human immunodeficiency virus type 1 (HIV-1) or type 2
             (HIV-2) antibody positive, or tests positive for HIV-1 or -2 at screening

          -  Participant has any condition for which, in the opinion of the investigator,
             participation would not be in the best interest of the participant (example,
             compromise the well being) or that could prevent, limit, or confound the protocol
             specified assessments

          -  Participants with a history of allergic reactions to any of the penicillins,
             cephalosporins, monobactams, carbapenems, or beta lactamase inhibitors (clavulanate,
             sulbactam, tazobactam, avibactam), or other contra indications for the use of
             piperacillin/tazobactam

          -  Participant with a history of clinically significant drug allergy such as, but not
             limited to, sulfonamides, or drug allergy diagnosed in previous studies with
             experimental drugs

          -  Participant has known allergies, hypersensitivity, or intolerance to lumicitabine or
             its excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

